Shares of Aemetis, Inc (NASDAQ:AMTX) have been given a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.

Brokers have set a one year consensus target price of $2.00 for the company and are expecting that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also given Aemetis an industry rank of 69 out of 265 based on the ratings given to its competitors.

Several research analysts recently commented on AMTX shares. FBR & Co reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Aemetis in a research note on Saturday, August 19th. Zacks Investment Research raised shares of Aemetis from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, B. Riley reaffirmed a “hold” rating and issued a $2.00 target price on shares of Aemetis in a research note on Monday, November 13th.

TRADEMARK VIOLATION WARNING: “Aemetis, Inc (AMTX) Given Average Recommendation of “Hold” by Analysts” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at

Aemetis (AMTX) traded up $0.01 during mid-day trading on Tuesday, hitting $0.71. 3,100 shares of the company’s stock traded hands, compared to its average volume of 49,475. Aemetis has a 52-week low of $0.53 and a 52-week high of $2.50. The company has a current ratio of 0.37, a quick ratio of 0.20 and a debt-to-equity ratio of -1.87.

An institutional investor recently raised its position in Aemetis stock. Geneva Advisors LLC boosted its stake in Aemetis, Inc (NASDAQ:AMTX) by 3.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,562,431 shares of the specialty chemicals company’s stock after acquiring an additional 50,800 shares during the period. Geneva Advisors LLC owned 7.93% of Aemetis worth $2,078,000 at the end of the most recent reporting period. Institutional investors own 18.64% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc is an international renewable fuels and biochemicals company. The Company is focused on the production of fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into biorefineries.

Get a free copy of the Zacks research report on Aemetis (AMTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aemetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.